- Oscillating positive expiratory pressure (OPEP) devices, used for airway clearance therapy, are becoming essential in managing chronic respiratory conditions by helping patients mobilize and expel mucus, thereby improving lung function and reducing infections in both homecare and clinical settings
- The rising demand for OPEP devices is primarily driven by the increasing prevalence of respiratory disorders such as COPD, asthma, and cystic fibrosis, along with a growing preference for non-invasive, portable, and patient-friendly treatment options
- North America dominated the oscillating positive expiratory pressure (OPEP) market with the largest revenue share of 40.5% in 2024, characterized by high disease awareness, advanced healthcare infrastructure, and supportive reimbursement policies, especially in the U.S., where home respiratory therapy is seeing increased adoption amid a shift toward patient-centric care
- Asia-Pacific is expected to be the fastest growing region in the oscillating positive expiratory pressure (OPEP) market during the forecast period due to rising burden of respiratory diseases, growing elderly population, and increased healthcare investments
- Facemask OPEP Devices segment dominated the oscillating positive expiratory pressure (OPEP) market with a market share of 50.5% in 2024, driven by its superior patient comfort, ease of use, and suitability for a wide range of age groups and respiratory conditions
